CL2015001786A1 - Composicion farmaceutica que comprende n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida, un agente efervescente alcalino y un lubricante alternativo; formulacion de granulacion por via humeda; formulacion de compactacion con rodillo; y formulacion por compactacion directa. - Google Patents

Composicion farmaceutica que comprende n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida, un agente efervescente alcalino y un lubricante alternativo; formulacion de granulacion por via humeda; formulacion de compactacion con rodillo; y formulacion por compactacion directa.

Info

Publication number
CL2015001786A1
CL2015001786A1 CL2015001786A CL2015001786A CL2015001786A1 CL 2015001786 A1 CL2015001786 A1 CL 2015001786A1 CL 2015001786 A CL2015001786 A CL 2015001786A CL 2015001786 A CL2015001786 A CL 2015001786A CL 2015001786 A1 CL2015001786 A1 CL 2015001786A1
Authority
CL
Chile
Prior art keywords
formulation
compaction
dimethylpiperazin
dimethoxyphenyl
pyrazol
Prior art date
Application number
CL2015001786A
Other languages
English (en)
Inventor
Noel Alan Weldon Baker
Alpesh Mistry
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49998566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001786(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2015001786A1 publication Critical patent/CL2015001786A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2015001786A 2012-12-21 2015-06-19 Composicion farmaceutica que comprende n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida, un agente efervescente alcalino y un lubricante alternativo; formulacion de granulacion por via humeda; formulacion de compactacion con rodillo; y formulacion por compactacion directa. CL2015001786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261740520P 2012-12-21 2012-12-21

Publications (1)

Publication Number Publication Date
CL2015001786A1 true CL2015001786A1 (es) 2015-08-14

Family

ID=49998566

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001786A CL2015001786A1 (es) 2012-12-21 2015-06-19 Composicion farmaceutica que comprende n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida, un agente efervescente alcalino y un lubricante alternativo; formulacion de granulacion por via humeda; formulacion de compactacion con rodillo; y formulacion por compactacion directa.

Country Status (26)

Country Link
US (2) US20140179712A1 (es)
EP (1) EP2934494B1 (es)
JP (1) JP6328138B2 (es)
KR (1) KR20150096787A (es)
CN (1) CN104853750B (es)
AR (1) AR094203A1 (es)
AU (1) AU2013366023B2 (es)
BR (1) BR112015014200A2 (es)
CA (1) CA2893480C (es)
CL (1) CL2015001786A1 (es)
CR (1) CR20150320A (es)
DO (1) DOP2015000127A (es)
ES (1) ES2742400T3 (es)
HK (1) HK1212229A1 (es)
IL (1) IL239521A0 (es)
MX (1) MX368670B (es)
NI (1) NI201500087A (es)
PE (1) PE20151418A1 (es)
PH (1) PH12015501389A1 (es)
RU (1) RU2674978C2 (es)
SG (1) SG11201504769WA (es)
TW (1) TWI651085B (es)
UA (1) UA115342C2 (es)
UY (1) UY35244A (es)
WO (1) WO2014096828A1 (es)
ZA (1) ZA201505197B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
WO2024031226A1 (zh) * 2022-08-08 2024-02-15 无锡和誉生物医药科技有限公司 Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB843940A (en) 1955-09-27 1960-08-10 Kodak Ltd Method of processing photographic silver halide emulsions containing colour couplers
BE667399A (es) 1964-07-30 1965-11-16
JPS57150846A (en) 1981-03-13 1982-09-17 Konishiroku Photo Ind Co Ltd Photographic element
JPS63133152A (ja) 1986-11-26 1988-06-04 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
JPH0467645A (ja) 1990-07-09 1992-03-03 Nec Kyushu Ltd バーンイン装置
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
JP2890065B2 (ja) 1990-11-10 1999-05-10 コニカ株式会社 ハロゲン化銀写真感光材料
JPH04184437A (ja) 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd カラー画像形成方法及びハロゲン化銀カラー写真感光材料
JPH04292322A (ja) 1991-03-19 1992-10-16 Fujitsu Ltd ラック給排装置
JPH0511414A (ja) 1991-07-02 1993-01-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
CA2119155C (en) 1991-10-18 1999-06-15 Dennis Paul Phillion Fungicides for the control of take-all disease of plants
WO1993019054A1 (en) 1992-03-26 1993-09-30 Dowelanco N-heterocyclic nitro anilines as fungicides
HRP921338B1 (en) 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
TW240217B (es) 1992-12-30 1995-02-11 Glaxo Group Ltd
JP3156026B2 (ja) 1993-12-27 2001-04-16 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
EP0788358B1 (en) 1994-11-10 2004-03-31 Millennium Pharmaceuticals, Inc. Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PL334250A1 (en) 1996-12-23 2000-02-14 Du Pont Pharm Co Nitrogen containing hetero-aromatic compounds and inhibitors of xa factor
EP1012150A4 (en) 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
JP3310226B2 (ja) 1998-10-16 2002-08-05 松下電器産業株式会社 音声合成方法および装置
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CA2362381C (en) 1999-02-10 2009-12-22 Welfide Corporation Amide compounds and medicinal use thereof
WO2000049001A2 (en) 1999-02-16 2000-08-24 E.I. Du Pont De Nemours And Company Phenoxy-, phenylthio-, phenylamino-, benzyloxy-, benzylthio- or benzylaminopyrimidine insectidices and acaricides
CA2383555C (en) 1999-08-12 2009-02-17 Paolo Pevarello 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
US6552008B1 (en) 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
WO2002024656A1 (fr) 2000-09-22 2002-03-28 Nihon Nohyaku Co., Ltd. Derives de n-(4-pyrazolyl amide, produits chimiques pour utilisation agricole et horticole et applications desdits derives
AU2002222683B9 (en) 2000-12-18 2021-12-23 Institute Of Medicinal Molecular Design, Inc Inflammatory cytokine release inhibitor
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
CN100379410C (zh) 2002-06-05 2008-04-09 株式会社医药分子设计研究所 糖尿病治疗药
JPWO2003103658A1 (ja) 2002-06-05 2005-10-06 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2003103665A1 (ja) 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ccr4アンタゴニストおよびその医薬用途
WO2004013137A1 (en) 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
RS20050789A (sr) 2003-05-01 2008-04-04 Bristol-Myers Squibb Company, Aril-supstituisana jedinjenja pirazol-amida pogodna za primenu kao inhibitori kinaze
US7115359B2 (en) 2003-07-25 2006-10-03 Konica Minolta Medical & Graphic, Inc. Photothermographic material
EP1664032B1 (en) 2003-08-21 2008-11-05 OSI Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
US7432271B2 (en) 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
US20050165074A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Amide derivatives as C-KIT modulators
ATE473967T1 (de) 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
JP2007535551A (ja) 2004-04-28 2007-12-06 バーテックス ファーマシューティカルズ インコーポレイテッド Rockおよび他のプロテインキナーゼの阻害剤として有用な組成物
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
RU2008107868A (ru) 2005-08-02 2009-09-10 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназ
EP1945190A1 (en) * 2005-09-22 2008-07-23 Swissco Devcelopment AG Effervescent metformin composition and tablets and granules made therefrom
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
WO2010121323A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
JP5614557B2 (ja) * 2009-05-27 2014-10-29 ダサン メディケム カンパニー リミテッド 発泡層を含む多層錠剤
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Also Published As

Publication number Publication date
US20170119759A1 (en) 2017-05-04
PE20151418A1 (es) 2015-10-21
CA2893480C (en) 2021-01-12
EP2934494A1 (en) 2015-10-28
CN104853750B (zh) 2018-06-26
ZA201505197B (en) 2017-07-26
BR112015014200A2 (pt) 2017-07-11
AU2013366023A1 (en) 2015-06-18
ES2742400T3 (es) 2020-02-14
US10420764B2 (en) 2019-09-24
TWI651085B (zh) 2019-02-21
CA2893480A1 (en) 2014-06-26
WO2014096828A1 (en) 2014-06-26
JP2016503782A (ja) 2016-02-08
EP2934494B1 (en) 2019-06-12
TW201431553A (zh) 2014-08-16
DOP2015000127A (es) 2015-07-31
PH12015501389A1 (en) 2015-09-02
RU2674978C2 (ru) 2018-12-14
IL239521A0 (en) 2015-08-31
UA115342C2 (uk) 2017-10-25
MX2015008067A (es) 2016-04-25
CR20150320A (es) 2015-09-11
NI201500087A (es) 2016-02-16
AU2013366023B2 (en) 2016-10-27
RU2015126345A (ru) 2017-01-30
SG11201504769WA (en) 2015-07-30
KR20150096787A (ko) 2015-08-25
HK1212229A1 (en) 2016-06-10
UY35244A (es) 2014-01-31
MX368670B (es) 2019-10-10
CN104853750A (zh) 2015-08-19
US20140179712A1 (en) 2014-06-26
JP6328138B2 (ja) 2018-05-23
AR094203A1 (es) 2015-07-15

Similar Documents

Publication Publication Date Title
IL238551B (en) Preparations containing 3-(6-(1-(2,2-difluorobenzo[1,3][d]dioxol-5-yl)cycloproponecarboxamide)-3-methylpyridin-2-yl)benzoic acid and n-(5-hydroxy- 2,4-di-tert-butyl-phenyl)-4-oxo-h1-quinoline-3-carboxamide and their uses
IL251647A0 (en) Oral veterinary preparations for the treatment of parasites containing active factors that act systemically, methods and uses thereof
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
ZA201405590B (en) Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
FR3010900B1 (fr) Composition cosmetique comprenant une association d'agents tensioactifs de types carboxylate, acyl-isethionate, et alkyl(poly)glycoside.
AR088936A1 (es) Formulaciones farmaceuticas
WO2014153009A3 (en) Thiosaccharide mucolytic agents
DK2667856T3 (da) Medicinsk indretning indeholdende en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens, og en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens
BR112015014885A2 (pt) combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos.
CL2014002558A1 (es) Sales de 5-[(1r)-2-([2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil]amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona; composicion y combinacion farmaceutica que las comprende y uso en el tratamiento del asma o epoc.
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CL2015001786A1 (es) Composicion farmaceutica que comprende n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida, un agente efervescente alcalino y un lubricante alternativo; formulacion de granulacion por via humeda; formulacion de compactacion con rodillo; y formulacion por compactacion directa.
BR112014017217A2 (pt) agente e composição farmacêutica
FR2993776B1 (fr) Agent actif et compositions cosmetiques anti-rides.
Fujita Stabilization of a Formaldehyde-Sensitive Drug Substance by Meglumine and a Compression-Sensitive Drug Substance by a Wet-Granule Tableting Method
TR200805337A2 (tr) Valsartan etkin maddesini içeren yeni oral farmasötik formülasyonlar